S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:IMTX

Immatics (IMTX) Stock Price, News & Analysis

$10.61
-0.23 (-2.12%)
(As of 04/12/2024 ET)
Today's Range
$10.50
$10.93
50-Day Range
$10.51
$12.94
52-Week Range
$5.92
$13.16
Volume
266,159 shs
Average Volume
504,425 shs
Market Capitalization
$898.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Immatics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
10.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Immatics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.44) to ($1.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.02 out of 5 stars

Medical Sector

2782nd out of 2,784 stocks

Biological Products, Except Diagnostic Industry

463rd out of 465 stocks

IMTX stock logo

About Immatics Stock (NASDAQ:IMTX)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial; and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTX Stock Price History

IMTX Stock News Headlines

1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
Cantor sees strong year ahead for oncology M&A
1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
Immatics Announces Proposed Public Offering
Analyzing Immatics' Multi-Faceted Investment Case
IMTX Oct 2023 10.000 put
Immatics shares rise on Moderna cancer collaboration
See More Headlines
Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/12/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMTX
Fax
N/A
Employees
432
Year Founded
N/A

Profitability

Net Income
$-104,980,000.00
Net Margins
-179.67%
Pretax Margin
-179.63%

Debt

Sales & Book Value

Annual Sales
$58.44 million
Book Value
$2.88 per share

Miscellaneous

Free Float
81,864,000
Market Cap
$898.24 million
Optionable
Optionable
Beta
0.67
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Harpreet Singh Ph.D. (Age 49)
    CEO, MD, Member of Management Board & Executive Director
    Comp: $897.96k
  • Dr. Toni Weinschenk Ph.D. (Age 50)
    Co-Founder & Chief Innovation Officer
  • Mr. Arnd Christ MBA (Age 58)
    Chief Financial Officer
  • Mr. Steffen Walter Ph.D. (Age 47)
    Chief Operations Officer
  • Mr. Edward A. Sturchio J.D. (Age 48)
    General Counsel & Secretary
  • Dr. Carsten Reinhardt M.D. (Age 57)
    Ph.D., Chief Development Officer
  • Mr. Cedrik M. Britten M.D. (Age 48)
    Chief Medical Officer
  • Mr. Jordan Silverstein (Age 44)
    Head of Strategy
  • Dr. Hans-Georg Rammensee Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Mr. Ephraim Hofsäß M.Sc.
    Vice President of SEC Reporting & Accounting

IMTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immatics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings
or view top-rated stocks.

How have IMTX shares performed in 2024?

Immatics' stock was trading at $10.53 at the beginning of the year. Since then, IMTX shares have increased by 0.8% and is now trading at $10.61.
View the best growth stocks for 2024 here
.

Are investors shorting Immatics?

Immatics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,910,000 shares, an increase of 6.2% from the March 15th total of 8,390,000 shares. Based on an average trading volume of 526,500 shares, the days-to-cover ratio is presently 16.9 days.
View Immatics' Short Interest
.

When is Immatics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our IMTX earnings forecast
.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) posted its earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The firm earned $7.60 million during the quarter, compared to analyst estimates of $13.28 million. Immatics had a negative net margin of 179.67% and a negative trailing twelve-month return on equity of 43.58%.

What ETFs hold Immatics' stock?

ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMTX) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners